BIOMAT Database Logo BIOMAT Database Logo

4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors. 2014

Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Research Center for Medicinal Chemistry, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon 305-343, Republic of Korea.

Erythropoietin-producing hepatocellular receptor tyrosine kinase subtype A2 (EphA2) is an attractive therapeutic target for suppressing tumor progression. In our efforts to discover novel small molecules to inhibit EphA2, a class of compound based on 4-substituted quinazoline containing 7-(morpholin-2-ylmethoxy) group was identified as a novel hit by high throughput screening campaign. Structural modification of parent quinazoline scaffolds by introducing substituents on aniline displayed potent inhibitory activities toward EphA2.

UI MeSH Term Description Entries
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D036104 Receptor, EphA2 An Eph family receptor found abundantly in tissues of epithelial origin. It is expressed in a diverse array of tissues during embryonic development, suggesting that it may play a role in embryogenesis. In adult tissues high levels of the receptor are expressed in the LUNG; SKIN; SMALL INTESTINE and OVARY. EphA2 Protein,EphA2 Receptor,EphA2 Receptor Tyrosine Kinase,EphA2-Tyrosine Kinase,Epithelial Cell Kinase Protein,Mammary-Derived Tyrosine Kinase 2,EphA2 Tyrosine Kinase,Mammary Derived Tyrosine Kinase 2

Related Publications

Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
March 2016, Bioorganic & medicinal chemistry letters,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
January 2011, ChemMedChem,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors.
October 2010, Bioorganic & medicinal chemistry letters,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Synthesis, antimicrobial evaluation, and docking studies of novel 4-substituted quinazoline derivatives as DNA-gyrase inhibitors.
October 2010, Archiv der Pharmazie,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
January 2013, PloS one,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
October 2013, Bioorganic & medicinal chemistry letters,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
September 2016, Journal of medicinal chemistry,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Development of (4-Phenylamino)quinazoline Alkylthiourea Derivatives as Novel NF-κB Inhibitors.
June 2022, Pharmaceuticals (Basel, Switzerland),
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors.
April 2016, Archives of pharmacal research,
Chae Jo Lim, and Kwang-Seok Oh, and Jae Du Ha, and Jeong Hyun Lee, and Ho Won Seo, and Chong Hack Chae, and Dae-Ghon Kim, and Mi-Jin Lee, and Byung Ho Lee
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido
August 2000, Journal of medicinal chemistry,
Copied contents to your clipboard!